Option chain shows key data for Palisade Bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Palisade Bio.

Palisade Bio (NASDAQ:PALI) Stock, Option Chain

Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

amd shutter

News

Intraday Update

Markets

Movers

AKAN

ASTE

ATEN

CDNA

CETX

CHEF

CNDT

CTMX

CVRX

DBRG

DPSI

GETR

GRMN

IMCC

LGHL

LMND

MNDR

NARI

NCLH

NYCB

PALI

PINS

PLTN

POAI

POWL

PSNY

RCKY

ROOT

SBUX

SITE

SMCI

SOBR

SRDX

STGW

SWKS

TECH

TGTX

TMDX

UFPT

XTIA

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

wall street chart shutter3

Earnings

Eurozone

Commodities

Trading Ideas

AMZN

US Stocks Mixed; Amazon Posts Upbeat Earnings

Stock Market

ABEO

HIBB

JBLU

OPRT

Crude Oil Moves Higher; General Motors Earnings Top Views

Palisade Bio Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Paliburg Holdings Ltd

PALISADES GOLDCORP LTD by PALISADES GOLDCORP LTD.

Palisades Goldcorp Ltd

Jefferies analyst Roger Song maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and lowers the price target from $32 to $28.

Price Target

Analyst Ratings

KURA

Jefferies Maintains Buy on Kura Oncology, Lowers Price Target to $28

Jefferies analyst Brent Thill maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $145 to $180.

SNOW

Jefferies Maintains Buy on Snowflake, Raises Price Target to $180

Contracts

Verizon Business Secures 5-Year Agreement With USDA Valued At Over $21M In First Year

Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>, JFBRW))), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that it has entered into a patent licensing agreement (the "Licensing Agreement"), with Xiamen Fast Power Co., Ltd. ("Xiamen"), a Chinese company specializing in advanced photovoltaic technology. This Licensing Agreement grants Jeffs' Brands the right to use the registered patent number 6345668 owned by Xiamen, which covers innovative waterproof photovoltaic board technology, for a period of three years in exchange for royalty payments.
The Licensing Agreement marks a significant milestone for Jeffs' Brands, enabling the Company to diversify its product offerings and enhance its e-commerce portfolio on the Amazon Marketplace. Pursuant to the agreement, Jeffs' Brands will receive an exclusive right to market and sell the patented technology solely through Amazon, without geographical restrictions, aiming to target a global customer base.
Under the terms of the Licensing Agreement, Jeffs' Brands will pay royalties to Xiamen on a quarterly basis, equal to 15% of the net cash flow profit generated from sales made using the patented technology on the Amazon Marketplace.

JFBR

Jeffs' Brands Enters Into A Patent Licensing Agreement To Market And Sell Photovoltaic Technology On Amazon

Biotech

General

GTBP

GT Biopharma Announces Partnership With University Of Minnesota For Phase 1 Clinical Trial Of GTB-3650 Tri-Specific Killer Engager For High-Risk MDS, Refractory/Relapsed AML, And Minimal Residual Disease; University To Sponsor IND Application.

WIIM

BRZE

Braze shares are trading higher following a report suggesting the company could be a target for an acquisition.

RBC Capital analyst Andrew Wong maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Outperform and raises the price target from C$75 to C$90.

TSX:CCO

RBC Capital Maintains Outperform on Cameco, Raises Price Target to C$90

Geopolitical tensions between Russia and Ukraine are once again roiling global energy markets, with rising prices raising concerns over the potential economic impact <a href="https://www.benzinga.com/topic/inflation">on U.S. consumer bills.</a> 
On Thursday, Russia launched an intercontinental ballistic missile (ICBM) from the Astrakhan region during an overnight strike on Dnipro, Ukraine, Reuters reported, citing the Ukrainian air force. 
As reported by Reuters, security experts said this marks the first use of an ICBM in a military conflict. The missiles are designed for nuclear warhead delivery. There is no indication the missile was nuclear-armed, Reuters said. 
Western officials disagree with Ukraine&#8217;s assessment, The New York Times <a href="https://www.nytimes.com/2024/11/21/world/europe/russia-ballistic-missile-ukraine-war.html">said in a report</a>, and say the missile was likely of intermediate range. The Times said the officials spoke anonymously in order to discuss a private Western intelligence assessment. 
The Ukrainian air force said the missile was fired from over 435 miles away, targeting the central-eastern city of Dnipro. 
While the attack caused injuries to two people, the extent of the damage remains unclear. Ukrainian president Volodymyr Zelenskyy condemned the move, commenting on X: &#8220;Our insane neighbour has once again revealed its true nature.&#8221;
The move adds to escalating tensions, coming on the heels of Ukraine firing two Western-made missiles at Russia on Tuesday and Wednesday, after receiving approval from the White House <a href="https://www.benzinga.com/news/global/24/11/42064198/putin-revises-nuclear-doctrine-for-broader-strikes-after-us-backed-ukrainian-attack-markets-drop-bonds-gain">to target Russian territory.</a>
<h3 class="wp-block-heading">US Natural Gas Prices Spike, Eye Best Monthly Performance Since July 2022</h3>
In the wake of these heightened external geopolitical risks, U.S. natural gas prices surged. 
Futures tied to the Henry Hub benchmark – as tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – jumped more than 6% on Thursday, reaching $3.40 per million British thermal units — the highest level since early November 2023.
The commodity is now up 50% for November, positioning itself for its strongest monthly rally since July 2022.
Natural gas demand in the U.S. has been driven by plummeting temperatures, intensifying the need for heating. 
The National Oceanic and Atmospheric Administration warned on Thursday of the season&#8217;s first significant snowfall in the central and northern Appalachians, with heavy accumulation expected through Friday.
&#8220;Higher elevations will have the best chance of significant accumulations, however even the lower elevations of central and northern Pennsylvania and south central New York will likely see some accumulation of snow,&#8221; the NOAA wrote in a post on X.
The U.S. Energy Information Administration is set to release weekly natural gas inventory change later Thursday.
Europe's natural gas market is grappling with fresh supply concerns as winter approaches after Austria&#8217;s OMV Group disclosed over the weekend that it will no longer receive volumes from its long-term contract with Russia's Gazprom.
<h3 class="wp-block-heading">WTI Oil Prices Climb, Gold Eyes 4th Straight Positive Day</h3>
The ripple effects of escalating geopolitical tensions also extended to crude oil markets. 
West Texas Intermediate crude futures, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), climbed 2.2% on Thursday morning, trading at $70 per barrel — the highest level since Nov. 11.
Gold continued to attract demand for safe-haven assets, with the precious metal rising 0.6% to $2,665 per ounce, eyeing the fourth straight session of gains. 
Bitcoin rose 3%, hitting a new peak of $98,367.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097545/feds-bowman-warns-on-inflation-risks-signals-neutral-rate-may-be-closer">Fed&#8217;s Bowman Warns On Inflation, Says Neutral Interest Rates May Be Closer &#8216;Than We Currently Think&#8217;</a></li>
</ul>

Specialty ETFs

Global

Economics

ETFs

$BTC

Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia

Janney Montgomery Scott analyst Robert Farnam downgrades Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) from Buy to Neutral and announces $176 price target.

Downgrades

Janney Montgomery Scott Downgrades Hanover Insurance Gr to Neutral, Announces $176 Price Target

RBC Capital analyst Irene Nattel reiterates Metro (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRU#TSX">MRU</a>) with a Sector Perform and maintains C$90 price target.

Reiteration

TSX:MRU

RBC Capital Reiterates Sector Perform on Metro, Maintains C$90 Price Target

SRAD

Sportradar shares are trading higher after the company announced a multiyear agreement with MLB to provide sports performance analysis of prospects using its Synergy Coaching and Scouting solution.

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) disclosed a contract from renewable energy company, RWE AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>), to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42105671/rwe-to-harness-ai-driven-weather-modelling-with-hpe-private-cloud-ai" rel="noreferrer noopener">enhance weather data analysis</a>.
RWE has adopted HPE Private Cloud AI, part of the NVIDIA AI Computing by HPE portfolio, to streamline weather model data processing and enhance information retrieval with retrieval-augmented generation (RAG).
The on-premise solution allows RWE&#8217;s researchers to rapidly deploy private cloud AI infrastructure within policy frameworks, enabling quicker experimentation and scaling of AI projects across various domains and regions.
HPE Private Cloud AI, co-developed with NVIDIA and delivered via the HPE GreenLake cloud, offers RWE a streamlined platform for infrastructure management, process automation, and workload orchestration, including sustainability metrics.
This allows RWE&#8217;s research team to focus on model development, accelerating time-to-market and providing a competitive edge in the renewable energy sector.
Fidelma Russo, EVP &amp; GM, Hybrid Cloud &amp; CTO at HPE, said, &#8220;The ability to fine tune and inference AI-driven weather models will be a key enabler to unlock higher efficiencies for RWE&#8217;s renewable energy portfolio and will give them a significant competitive advantage in the market.&#8221;
&#8220;HPE Private Cloud AI is a unique turnkey solution that enables RWE&#8217;s researchers to reach the market quicker and handle massive datasets.&#8221;
Yesterday, Deloitte expanded its collaboration with HPE to implement the newly launched HPE Private Cloud AI with NVIDIA, enhancing its AI capabilities and accelerating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42085548/deloitte-and-hewlett-packard-enterprise-collaborate-to-deliver-private-cloud-ai-capabilities" rel="noreferrer noopener">deployment of Generative AI solutions</a>.
Investors can gain exposure to the stock via&nbsp;First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>) and Roundhill Generative AI &amp; Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHAT#NYSE">CHAT</a>).
Price Action: HPE shares are up 0.99% at $21.39 premarket at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42105704" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship&#8217;s 6th Test Flight</a></li>
</ul>

Equities

Large Cap

CHAT

KNGZ

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

HPE Powers RWE's Renewable Energy with AI Weather Modeling

RBC Capital analyst Andrew Wong maintains NexGen Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) with a Outperform and raises the price target from C$10 to C$15.

TSX:NXE

RBC Capital Maintains Outperform on NexGen Energy, Raises Price Target to C$15

ROAD

Construction Partners shares are trading higher after the company raised its FY25 revenue guidance.

Addentax Group Corp. ("Addentax" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced the signing of a Memorandum of Understanding (MOU) for nationwide strategic cooperation with Shenzhen Yingbin Brand Development Co., Ltd. ("Yingbin Brand"), a prominent brand management company headquartered in Guangdong.

ATXG

Addentax Group Corp. Announces Signing Of MOU For Strategic Cooperation With Shenzhen Yingbin Brand Development Co., Ltd., Offering A Wide Range Of Services In Brand Supply Chain Management, Product Supply Chain Solutions, And Marketing Supply Chain Strategies

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

iQIYI shares are trading lower despite a Q3 earnings beat.

RBC Capital analyst Pammi Bir maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Outperform and raises the price target from C$21 to C$22.

TSX:REI

TSX:REI/UN

RBC Capital Maintains Outperform on Riocan REIT, Raises Price Target to C$22

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

SWVL

Swvl Signs Three-Year Contract With G4S In Saudi Arabia To Provide SaaS-Based Mobility Solutions, Enhancing Fleet Efficiency Across Riyadh, Jeddah, And Dammam With Over 14,000 Monthly Trips; Financial Terms Not Disclosed

Warning: PALI is at high risk of performing badly

Palisade Bio GAAP EPS of -$2.32 beats by $1.03

"I am extremely proud of the clinical progress our team has made over this past quarter. The initiation of our Phase 1 clinical trial and patient e...

Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year

As of September 30, 2024, the Company had cash and cash equivalents of $8.0 million. The Company believes it has sufficient cash to fund its curren...

Palisade Bio expects cash to fund operations through 1Q25

Maxim lowered the firm's price target on Palisade Bio (PALI) to $8 from $22.50 and keeps a Buy rating on the shares. The company reported Q3 result...

Palisade Bio price target lowered to $8 from $22.50 at Maxim

Brookline initiated coverage of Palisade Bio (PALI) with a Buy rating and $38 price target Palisade Bio is advancing novel therapeutics for patient...

Palisade Bio initiated with a Buy at Brookline

Press Releases

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Comments

Palisade Bio

Palisade Bio (PALI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga